… Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In this
pre-specified analysis of the DAPA-CKD trial, we determined the effects of dapagliflozin on …

… Accepting that this study included a small subgroup of DAPA-CKD participants and that the
… , no prior trial of any therapeutic agent in IgA nephropathy has demonstrated an effect of this …

… the DAPA-CKD trial, we were able to explore the effects of SGLT2 inhibitors in patients with
chronic kidney disease due … , ischaemia or hypertensive chronic kidney disease, and other or …

… The results of the trial showed that dapagliflozin compared with … the DAPA-CKD trial, we
assessed the effect of dapagliflozin on albuminuria, investigated the consistency of these effects …

… In this prespecified analysis of the DAPA-CKD trial, we demonstrate that the effects of
dapagliflozin on kidney failure, heart failure, and mortality outcomes were consistent regardless of …

… may derive greater absolute benefit from dapagliflozin, or whether there are subpopulations
… of the DAPA-CKD trial, we examined the efficacy and safety of dapagliflozin according to …

… In this prespecified analysis of the DAPA‐CKD trial, we aimed to examine whether … effects
of dapagliflozin on kidney and cardiovascular end points and on safety in patients with CKD …

… , the DAPA-CKD trial included participants with CKD but without … enrolled in the DAPA-CKD
trial and compare these with … recent trials involving participants with T2D and/or CKD from …

… CKD, but they have to be confirmed in the DAPA-CKD study. In summary, the DAPA-CKD
study is the first dedicated clinical trial to … in patients across multiple CKD stages both with and …

… study In this prespecified analyses of the DAPA-CKD trial, we assessed the effect of
dapagliflozin on eGFR slope by establishing the effect of dapagliflozin on changes in eGFR during …